DEFENDO Long Term Follow-up Study in Stage 1 NK Patients

NCT05552261 · clinicaltrials.gov ↗

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Neurotrophic Keratitis

Interventions

DRUG: Cenegemin in the DEFENDO Study

Sponsor

Dompé Farmaceutici S.p.A